Sloan Sheldon

Chief Medical OfficerSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed May 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.6M
Net Open-Market Flow
-$5.6M
Transactions
9
8 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)78K$27.46$2.2M78K
May 1, 2026Sell(S)21K$69.53$1.5M57K
May 1, 2026Sell(S)20K$70.61$1.4M37K
May 1, 2026Sell(S)9K$71.56$628K29K
May 1, 2026Sell(S)13K$72.94$932K16K
May 1, 2026Sell(S)10K$73.74$764K5K
May 1, 2026Sell(S)5K$74.60$377K400
May 1, 2026Sell(S)400$75.37$30K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)78K$0322K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002038798-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: